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ttp://dx.doi.org/10.1016/j.ajpath.2014.03.006Obesity and metabolic syndrome are linked to an increased prevalence of breast cancer among post-
menopausal women. A common feature of obesity, metabolic syndrome, and a Western diet rich in
saturated fat is a high level of circulating cholesterol. Epidemiological reports investigating the rela-
tionship between high circulating cholesterol levels, cholesterol-lowering drugs, and breast cancer are
conﬂicting. Here, we modeled this complex condition in a well-controlled, preclinical animal model
using innovative isocaloric diets. Female severe combined immunodeﬁcient mice were fed a low-fat/no-
cholesterol diet and then randomized to four isocaloric diet groups: low-fat/no-cholesterol diet, with or
without ezetimibe (cholesterol-lowering drug), and high-fat/high-cholesterol diet, with or
without ezetimibe. Mice were implanted orthotopically with MDA-MB-231 cells. Breast tumors from
animals fed the high-fat/high-cholesterol diet exhibited the fastest progression. Signiﬁcant differences
in serum cholesterol level between groups were achieved and maintained throughout the study;
however, no differences were observed in intratumoral cholesterol levels. To determine the mechanism
of cholesterol-induced tumor progression, we analyzed tumor proliferation, apoptosis, and angiogen-
esis and found a signiﬁcantly greater percentage of proliferating cells from mice fed the high-fat/high-
cholesterol diet. Tumors from hypercholesterolemic animals displayed signiﬁcantly less apoptosis
compared with the other groups. Tumors from high-fat/high-cholesterol mice had signiﬁcantly higher
microvessel density compared with tumors from the other groups. These results demonstrate that hy-
percholesterolemia induces angiogenesis and accelerates breast tumor growth in vivo. (Am J Pathol
2014, 184: 2099e2110; http://dx.doi.org/10.1016/j.ajpath.2014.03.006)Supported by The Breast Cancer Research Foundation, The Fortin
Foundation, and NIH grant P01 CA045548 (M.A.M.).
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Disclosures: None declared.Breast cancer is the most frequent and second most deadly
cancer in women, with >230,000 new cases and nearly
40,000 estimated annual deaths in the United States alone.1
Most breast cancers are invasive ductal carcinomas that
have penetrated through the ductal wall and have invaded
surrounding breast tissue, often leading to metastasis to
other sites, including the lung, liver, and bone, resulting in
signiﬁcant morbidity, suffering, and death.
Breast cancer rates differ signiﬁcantly among nations
worldwide, with developed countries in North America and
Northern and Western Europe reporting the highest inci-
dence of breast cancer globally. The incidence of breast
cancer in these regions is three to four times higher than thestigative Pathology.
.incidence of breast cancer in parts of Asia and Africa.1 More
important, relocation studies have shown that women who
move from an area of low incidence of breast cancer (Japan)
to a high-incidence area (Los Angeles, CA) develop breast
cancer at rates similar to that of U.S. women, with the rate of
breast cancer incidence associated with the time of life at
immigration.2 For Japanese women who immigrated early
Pelton et alin life, the rate of breast cancer was signiﬁcantly higher than
in women who moved from Japan to Los Angeles later in
life, with both groups demonstrating a signiﬁcantly greater
incidence of breast cancer compared with women in their
homeland.2 These ﬁndings point to a possible dietary factor
in a traditional Western diet that may be contributing to
increased breast cancer incidence.2 Although speciﬁc di-
etary factors that increase the rate of breast cancer among
U.S. women are not well understood, some evidence sug-
gests a signiﬁcant, positive association between breast
cancer incidence and intake of saturated fat in post-
menopausal women.3 Moreover, both adult weight gain and
metabolic syndrome are linked to an increased prevalence of
breast cancer.4e6 A common feature shared by adult
obesity, metabolic syndrome, and a Western diet rich in fat
is a high level of circulating cholesterol.
Similar to other mammalian cells, breast ductal epithelial
cells synthesize cholesterol endogenously via the mevalonate
pathway and absorb cholesterol-containing lipoproteins from
the circulation. Consequently, control of cellular cholesterol
content is achieved by regulating systemic cholesterol con-
centration and by balancing intrinsic cellular metabolic pro-
cesses.7,8 Yet, despite the sophisticated mechanisms for
maintaining the appropriate cholesterol balance, it has been
reported that ductal epithelium of the breast may be sensitive
to systemic changes in serum cholesterol levels.9 These
changes may result in aberrant cellular responses to speciﬁc
growth factors and/or cytokines, resulting in altered patterns
of cellular growth, apoptosis, morphological characteristics,
and intercellular communication.
Retrospective epidemiological studies have suggested
that elevated serum cholesterol and/or hyperlipidemia in-
crease the rate of breast cancer among women of developed
countries.4,5,10 These case-controlled, cohort, or compara-
tive studies also reported that statin drugs, which inhibit the
rate-limiting step in cholesterol synthesis11 or the hydro-
phobic subclass of statins, decrease overall breast cancer
prevalence,12e15 reduce the rate of developing an estrogen
receptor/progesterone receptorenegative cancer, and pro-
mote a downward shift in breast cancer grade and stage.16
However, results from several large, prospective, epidemi-
ological studies examining the relationship between serum
cholesterol levels, cholesterol-lowering drugs, and breast
cancer incidence have been inconclusive.14,17,18 For
example, it has been shown that women with clinically high
(240 mg/dL) fasting total serum cholesterol have a slight,
but statistically signiﬁcant, increased incidence of breast
cancer.18 A separate study demonstrated that untreated, self-
reported high cholesterol was not associated with an
increased rate of breast cancer, even among obese and
postmenopausal women.14 A third study found that the
hydrophobic class of statins signiﬁcantly reduced the inci-
dence of invasive breast cancer among older women.13,15
In contrast to the previously described studies,17 which
suggested an association between statin use and decreased
incidence of breast cancer, a prospective study examining the2100effect of cholesterol-lowering drug use on many cancers
showed that the incidence of breast cancer was no different
among women reporting long-term statin use compared with
women who reported never having used statins. This latter
report adjusted for age and history of high cholesterol levels
but did not separate women on the basis of menopausal status.
Although the effect of statins on the incidence of primary
breast cancer remains unclear, epidemiological studies
report that lipophilic statin use among women diagnosed
with stage I to III breast cancer was associated with a
reduced rate of cancer recurrence.19e21 Taken together,
these numerous, inconsistent, and sometimes contradicting
epidemiological results highlight an important need for
studies that model the complex relationship between serum
cholesterol, cholesterol-lowering drugs, and breast cancer
using well-controlled, preclinical models.
As a function of the suggested links between post-
menopausal weight gain, metabolic syndrome, and breast
cancer,4e6 prior work describing an effect of elevated
cholesterol and statin drugs on breast cancer risk,4,5,12e14
and our own reports demonstrating a role for cholesterol
in prostate cancer progression,22e25 we chose to determine
whether hypercholesterolemia would promote breast cancer
progression in an in vivo model that tightly controlled other
metabolic variables associated with a Western diet.
It has been previously reported that a high-fat Western diet
promoted the growth of breast tumors in the MMTV-PyMT
breast cancer model in which tumor formation is driven by
polyoma middle T antigen26 and in the apolipoprotein E
(ApoE) knockout mouse.27 Although these studies suggested
that a Western diet promotes breast cancer growth, a speciﬁc
role for cholesterol was not established because isocaloric
diets were not compared and cholesterol was not speciﬁcally
targeted (as we have done in the current study).
By using novel diet and feeding strategies, we have
generated an innovative isocaloric diet approach in which
we are able to determine the speciﬁc effects of cholesterol in
mice. This approach provides the opportunity to study the
effects of hypercholesterolemia on tumor growth. In the
current study, we apply this approach to an orthotopic
xenograft model of human estrogen receptorenegative
breast cancer and demonstrate that a hypercholesterolemic
diet promotes the growth of breast cancer. This effect is
blocked by the hypocholesterolemic drug ezetimibe. His-
tological and biochemical analyses indicate that hypercho-
lesterolemia increased cell proliferation and tumor cell
apoptosis, and signiﬁcantly increased tumor angiogenesis.
To our knowledge, this is the ﬁrst report of a speciﬁc role
for cholesterol in promoting breast cancer growth.
Materials and Methods
Antibodies
The following antibodies were used: anti-CD31 monoclonal
antibody (rat anti-mouse); antieKi-67 primary antibodyajp.amjpathol.org - The American Journal of Pathology
Table 1 Diet Formulations
Diet component
HFHC LFNC
g% kcal% g% kcal%
Protein (casein, 30 mesh L-cysteine) 23 20 19 20
Carbohydrate (corn starch,
maltodextrin, sucrose, cellulose)
45 40 67 70
Fat (soybean oil, cocoa butter) 20 40 4 10
Cholesterol 1.25 0 0 0
Vitamin, mineral, other w10 0 10 0
Cholesterol Promotes Breast Tumor Growth(Abcam, Cambridge, MA); anti-smooth muscle actin
monoclonal antibody (Sigma, St. Louis, MO); Alexa Fluor
488econjugated goat anti-rat; Alexa Fluor 488econjugated
goat anti-mouse; Alexa Fluor 568econjugated goat anti-
rabbit; Alexa Fluor 568econjugated goat anti-mouse
(Invitrogen, Carlsbad, CA); and Cy3-conjugated Afﬁni-
Pure goat anti-rabbit IgG, Fc fragment speciﬁc (Jackson
ImmunoResearch, West Grove, PA).
Orthotopic Breast Tumor Model
Five-week-old female severe combined immunodeﬁcient
(SCID) mice, obtained from the Massachusetts General
Hospital (Boston), were fed a low-fat/no-cholesterol diet
(LFNC) (10% fat, 0% cholesterol, and 0% cholic acid; diet
D12102; Research Diets, NewBrunswick, NJ) (Table 1) for 3
weeks, followed by a blood draw from the saphenous tail vein
and serum cholesterol determination using the Inﬁnity
Cholesterol Liquid Stable Reagent (ThermoFisher Scientiﬁc,
Waltham, MA) (Figure 1 and Table 1). The mice were then
divided into high-fat/high-cholesterol diet (HFHC) (40% fat,
1.25% cholesterol, and 0% cholic acid; diet D12109;
Research Diets) (Table 1) and LFNC diet groups, with or
without 30 mg/kg per day ezetimibe (Merck, Whitehouse
Station, NJ), added to powdered food, and the mice continued
on their respective isocaloric diets for 4 weeks before tumor
implantation (Table 1). MDA-MB-231 breast cancer cells
were obtained in October 2005 from American Type Culture
Collection (ATCC;Manassas, VA) (catalog numberHTB-26,
lot number 3576801), grown as recommended and frozen
within two passages for long-term storage. On resuscitation,
MDA-MB-231 cells were expanded for <10 passages and
were maintained in culture for <6 weeks before in vivo im-
plantation. These cultured MDA-MD-231 cells were most
recently authenticated in February 2013 by short tandem
repeat DNA proﬁling (Genetica DNA Laboratories, Bur-
lington, NC). Comparative analysis of our MDA-MB-231
DNA proﬁle matched the known reference DNA proﬁle
of ATCC MDA-MD-231 (American National Standards
Institute/ATCC ASN-0002-2011), with 100% identity con-
ﬁrming the authentication of our MDA-MB-231. A total of
2 106 MDA-MD-231 cells were orthotopically injected per
site, with 1:1 volume of Matrigel (BD BioSciences, San Jose,
CA) into the fourth mammary fat pad of each animal (two
tumors per mice).28,29 To eliminate any injection bias, the
mice were randomized before implantation and the implanterThe American Journal of Pathology - ajp.amjpathol.org(K.P. or C.M.C.) was blinded to which group each mouse
was assigned. All animal procedures were done in compli-
ance with Boston Children’s Hospital (Boston, MA) animal
care and use policies. Tumors were measured every other day
from the initiation of the ﬁrst palpable tumors, and the mice
were sacriﬁced before reaching the maximum tumor burden
(87  1 day after implantation). Terminal bleeds for sero-
logical analysis were taken via cardiac puncture. Serum in-
sulin and estradiol tests were performed by the Vanderbilt
Hormone Assay and Analytical Core (Nashville, TN). Tri-
glyceride, bilirubin, and other liver function tests were per-
formed by the Yale University Mouse Phenotyping Center
(New Haven, CT). Tumors were removed and either placed
in optimal cutting temperature (OCT) solution (Tissue-Tek,
Torrance, CA) or snap frozen for analysis.
Tumor Cholesterol Analysis
Tumors were ﬁnely minced in PBS on ice and cholesterol
concentration was determined as described previously.30
Apoptosis Analysis
The percentage of apoptotic cells in tumors divided into
sections was determined by TUNEL assay using the In Situ
Cell Death Detection Kit (Roche Diagnostics Corp, Indi-
anapolis, IN). Brieﬂy, frozen tumor sections were ﬁxed in
4% paraformaldehyde and permeabilized, and the DNA was
stained with ﬂuorescein following the manufacturer’s pro-
tocol. Nuclei were counterstained with DAPI (Vector Labs,
Burlingame, CA). Images were captured using a Zeiss mi-
croscope (Carl Zeiss Microscopy, Jena, Germany), and the
positive cells and nuclei were counted using Axiovision 4.0
(Carl Zeiss Microscopy) and ImageJ software version
1.4.3.67 (NIH, Bethesda, MD).
Immunoﬂuorescence
Frozen tumor samples in OCT were divided into sections (3
to 20 mm thick), mounted on Superfrost slides (ThermoFisher
Scientiﬁc), and air dried for 30 minutes. Sections were ﬁxed
with cold acetone (5 minutes), followed by 1:1 acetone:ch-
loroform (5 minutes), and then acetone (5 minutes), or by
using 4% paraformaldehyde at room temperature (30 mi-
nutes), followed by 0.025% Triton X-100 (Sigma) in PBS (5
minutes) to permeabilize the cells. Sections were washed
with cold PBS 3 for 5 minutes, incubated in a blocking
solution of PBS/Tween (0.1%) containing 5% bovine serum
albumin (Sigma) at room temperature (30 minutes), and then
washed in cold PBS 3 for 5 minutes each. The appropriate
primary antibodies diluted 1:200 to 1:1000 in blocking so-
lution were incubated with the sections overnight at 4C.
Sections were then washed 3 for 5 minutes in cold PBS and
incubated in blocking solution (10 minutes). Sections were
then incubated with the appropriate ﬂuorescent reporter an-
tibodies diluted 1:500 to 1:5000 in blocking solution at room2101
Figure 1 Study design. A and B: A total of 120 female SCID mice (A) were maintained on a LFNC diet (B) for 3 weeks. C: Blood was drawn to measure serum
cholesterol concentration. Any mouse with serum cholesterol levels that did not normalize (means  SD) was removed from the study. D: Mice were then
randomized into four different diet/treatment groups: LFNC, with or without ezetimibe, and high fat/high cholesterol, with or without ezetimibe. E: Mice were
maintained on these diets for 4 weeks, and their serum cholesterol levels were monitored biweekly, at which point 2  106 MDA-MB-231 cells were
orthotopically injected into the fourth mammary fat pads (two tumors per mouse, approximately 28 to 30 mice per group). F: Mice were maintained on their
respective diets and were checked daily for tumor formation, and their blood was drawn every several weeks for serum cholesterol determination. After 4
weeks, when tumors appeared, tumor volume was measured three to four times per week until reaching maximum tumor volume. G: Mice were sacriﬁced, and
tumors were harvested and processed for analysis.
Pelton et altemperature (30 minutes), followed by washing 3 in PBS.
Nuclei were counterstained with DAPI. Ki-67e and
TUNEL-stained sections were imaged on a Zeiss microscope
at 20 magniﬁcation and quantiﬁed using ImageJ software.
Double staining of CD31 with smooth muscle actin (SMA)
was performed sequentially, as previously described.23
Blood vessels were imaged at 10 magniﬁcation on a
Zeiss microscope, and blood vessel analyses were conducted
using IPLab software version 3.6.3 (BD Biosciences Bio-
imaging, Rockville, MD), as previously described.31
Statistical Analysis
A two-way repeated-measures analysis of variance was
applied to assess the effects of diet and drug on tumor
volume over time. The F-test was used to test changes in
tumor growth for each diet and drug subgroup and to
compare the slopes between groups over the time course
(equivalent to area under the curve) after injection. Post hoc
Bonferroni comparisons were used to test mean differences
in tumor volume between the groups at speciﬁc days. A
mixed-model analysis of variance analysis using a diagonal
covariance structure was used to assess tumor characteristics
(TUNEL, Ki-67, microvessel density, and vessel stability
with SMA), and Bonferroni correction was used to adjust
for multiple pairwise comparisons. Serological measure-
ments, intratumoral cholesterol levels, and body mass were
analyzed using one-way analysis of variance and Bonfer-
roni’s multiple-comparison tests or t-test. Data are reported
in terms of the means  SEM. Statistical analyses were
performed using SPSS, version 19.0 (SPSS Inc./IBM,2102Chicago, IL), and GraphPad Prism version 5 for Windows
(GraphPad Software, San Diego, CA). Two-tailed values of
P < 0.05 were considered statistically signiﬁcant.
Results
The design of our cholesterol-targeted experimental
approach combines a diet regimen with a pharmaceutical
agent, ezetimibe (Zetia; Merck, Whitehouse Station, NJ),
which speciﬁcally targets cholesterol. In this protocol, we
used an LFNC diet, with or without 30 mg/kg per day
ezetimibe, and an HFHC diet (without sodium cholate), with
or without 30 mg/kg per day ezetimibe (Figure 1 and
Table 1). Because studies using statins cannot be interpreted
as demonstrating a cholesterol effect because statins do not
target cholesterol speciﬁcally,22,32 because cholesterol
metabolism and turnover is substantially different in the
mouse versus humans,32,33 and since statins cannot lower
serum cholesterol levels in normal mice,34,35 we used eze-
timibe to reduce serum cholesterol. Ezetimibe is a U.S. Food
and Drug Administrationeapproved drug that blocks dietary
cholesterol uptake in the gut, thereby lowering serum
cholesterol levels.36e38 Ezetimibe is a speciﬁc antagonist of
NPC1L1, the bona ﬁde gut cholesterol transporter.36 Unlike
statins, which do not speciﬁcally target cholesterol, ezeti-
mibe has no known target other than NPC1L1, a transporter
expressed exclusively in the jejunum and hepatocytes in
humans and only in the jejunum in mice.39
Female SCID mice were fed the LFNC diet for 3 weeks
and were then randomized to the four diets previously
described, with calorie intake set at 21.18 calories per day inajp.amjpathol.org - The American Journal of Pathology
Cholesterol Promotes Breast Tumor Growthall groups. This produced four cohorts of mice with
signiﬁcantly distinct cholesterol levels of 89.8  15.1,
95.9  15.9, 109.2  14.2, and 139.9  28.9 mg/dL, for the
LFNC þ ezetimibe, the LFNC, the HFHC þ ezetimibe, and
the HFHC cohorts, respectively (Figure 2A). As we have
described,24,26 both the diet and ezetimibe had statistically
signiﬁcant effects on murine serum cholesterol levels.
Prior in vivo studies of dietary fat and cholesterol often
control for caloric effects of high-fat diets by balancing the
control diets with additional carbohydrates,40 making the
animals hyperglycemic and increasing insulin levels, or in
other cases, do not control for energy at all.27,41 Given that
carbohydrate restriction and the resultant lower serum in-
sulin levels can also slow tumor growth,42 most diet studies
cannot separate the effects of insulin from the effects of
cholesterol on tumor growth. In the present study, we
observed normal serum insulin levels in mice at sacriﬁce
and there was no effect of diet or drug treatment on insulin
levels (PZ 0.702, analysis of variance) (Figure 2B). Given
that cholesterol is a precursor to steroid hormone synthesis,
including estrogen, which has a clear role in normalFigure 2 Increased serum cholesterol levels are associated with accelerated tu
LFNC diet, with or without ezetimibe (Z), and bled for cholesterol determination eve
just before the ﬁrst measurable tumors appeared are presented as serum cholesterol
one another (F Z 72.70, P < 0.0001), and this difference was maintained throu
signiﬁcance. Values <0.01 were considered signiﬁcant (n Z 28 per group). B: S
mL) SEM versus diet group. There was no difference in serum insulin levels betwee
variance; nZ 15 per group). C: Serum estradiol levels. Serum estradiol levels are
difference in serum estradiol levels between groups at sacriﬁce (PZ 0.332, analysi
drug on body weight. Average body mass is plotted as mass (g)  SEM versus die
implantation (PZ 0.135, analysis of variance), and no differences in body weigh
average body weight at tumor end point presacriﬁce (PZ 0.206, analysis of varian
mean tumor volume for each of the four groups after ﬁrst appearance. E: Signiﬁcant
compared with the LFNC diet (asterisks). The mice in the LFNC group had a redu
differences were also measured between tumor growth in mice fed an HFHC diet,
demonstrated a reduced rate of tumor growth (slope test: FZ 6.97, P< 0.001). G:
fed the LFNC versus LFNCþ ezetimibe diets. Data are presented as mean volume (m
variance. Two-tailed values of P < 0.05 were considered statistically signiﬁcant. H:
(as described in Materials and Methods). Tumor cholesterol is plotted as the avera
variance indicated no signiﬁcant difference in the intratumoral cholesterol levels
The American Journal of Pathology - ajp.amjpathol.orgmammary gland function and breast cancer, we veriﬁed that
ezetimibe- and diet-induced changes in serum cholesterol
levels did not alter serum estradiol levels (P Z 0.442,
analysis of variance) (Figure 2C). In addition, we conﬁrmed
that the isocaloric diet used in this study resulted in
signiﬁcantly different serum cholesterol levels without
leading to increased body mass in mice fed the high-fat diet
(with or without ezetimibe) (Figure 2D). Average body
mass did not differ between diet and drug groups at any
point in the study, as demonstrated by body weight data
presented at the time of tumor implantation (P Z 0.136,
analysis of variance) (Figure 2D) and at the time of tumor
end point and sacriﬁce (P Z 0.206, analysis of variance)
(Figure 2D). Moreover, all of the mice in the study main-
tained a normal body weight throughout the study.
After 4 weeks on the diets, mice were implanted with
2  106 MDA-MB-231 cells mixed in Matrigel into the
fourth mammary fat pad of the breast (two tumors per
mouse). Once tumors appeared (approximately 4 weeks; day
1) (Figure 2, EeG), they were measured every other day for
25 days, at which time the mice were sacriﬁced and themor growth. A: Serum cholesterol levels. Mice were fed either an HFHC or an
ry 3 to 4 weeks throughout the course of the study. Serum cholesterol levels
(mg/dL) versus diet cohort SEM. All groups were statistically different from
ghout the study. An analysis of variance was used to determine statistical
erum insulin levels. Serum insulin levels are plotted as insulin levels (ng/
n diet and ezetimibe (Z) treatment groups at sacriﬁce (PZ 0.278, analysis of
plotted as estradiol levels (ng/mL)  SEM versus diet group. There was no
s of variance; nZ 15 per group). D: Body mass. There was no effect of diet or
t group. There was no difference in animal body mass at the time of tumor
t between groups were observed throughout the study, as indicated by the
ce; nZ 27 to 30 animals per group). EeG: Tumor growth. Line graphs show
mean differences were observed between tumor growth in mice fed an HFHC
ced rate of tumor growth (slope test: F Z 2.05, P Z 0.04). F: Signiﬁcant
with and without ezetimibe (asterisks), where the ezetimibe-treated group
No signiﬁcant differences were measured between tumor growth in the mice
m3) SEM versus days. Statistical signiﬁcance was determined by analysis of
Tumor cholesterol. Cholesterol was extracted from tumor tissue and assayed
ge cholesterol (mg) tumor tissue (g)  SEM versus diet group. Analysis of
between groups (PZ 0.825) (nZ 11 tumors per group).
2103
Figure 3 Hypercholesterolemia, independent of diet/drug, is associated
with increased tumor volume. A: Bar graph shows the average ﬁnal tumor
volume (mm3)  SEM versus serum cholesterol group. Hypercholesterolemic
mice, blinded to drug/diet group, were deﬁned as animals possessing serum
cholesterol levels of 2 SDs higher than the mean of age-matched, sex-
matched mice receiving a normal diet (a value of 124 mg/dL cholesterol).
These hypercholesterolemic mice demonstrated a signiﬁcantly greater
average terminal tumor volume than animals with cholesterol levels <124
mg/dL cholesterol (751 372 mm3 versus 583 22 mm3; PZ 0.007, t-test)
(nZ 25 mice in124 mg/dL cholesterol group and 81 mice in<124 mg/dL
cholesterol group). The Pearson correlation, blinded to treatment, between
serum cholesterol and total tumor volume is positive (Pearson r Z 0.23,
PZ 0.018) and clearly reveals an association that animals with higher serum
cholesterol tend to have high tumor volumes. B: Hypercholesterolemic mice
do not have high serum insulin levels. Bar graph shows the average serum
insulin levels  SEM versus cholesterol. Mice with the highest serum
cholesterol levels (124 mg/dL), independent of treatment group, do not
have increased serum insulin levels. Mean serum insulin levels did not differ
between mice with hypercholesterolemia (124 mg/dL) and mice with
normal serum cholesterol levels (<124 mg/dL) (0.67  0.33 versus
0.73  0.31 ng/mL; PZ 0.48, t-test) (n Z 15 to 43 per group). No rela-
tionship between serum cholesterol and serum insulin exists (Pearson
rZ0.01, PZ 0.93). C: Serum insulin levels are not associated with tumor
volume. Animals with the highest serum insulin levels, deﬁned as serum
insulin levels 2 SDs above the mean, a value of 1.0 ng/mL, had a ﬁnal
average tumor volume that was the same tumor volume of animals with
normal serum insulin levels of<1.0 ng/mL (PZ 0.377, t-test) (nZ 8 to 49
animals per group). A Pearson correlation analysis blinded to treatment
group showed that no association exists between serum insulin levels and
tumor volume (Pearson rZ 0.140, PZ 0.30).
Pelton et altumors removed for analysis. Tumors from animals fed the
HFHC diet progressed fastest, whereas signiﬁcantly reduced
tumor growth rates were observed in the LFNC diet group
and the ezetimibe-treated HFHC diet group (Figure 2, E and
F). Repeated-measures analysis of variance indicated highly
signiﬁcant increases in tumor volume from baseline for each
of the four groups (all P < 0.01). In addition, the area under
the curve for the HFHC þ ezetimibe diet was signiﬁcantly
less, reﬂecting a slower rate of tumor growth, than the
HFHC diet (F Z 6.97, P < 0.01), where mean tumor vol-
ume was signiﬁcantly lower with ezetimibe on day 13
(PZ 0.026), day 16 (PZ 0.004), day 19 (P < 0.001), day
22 (P < 0.001), and day 25 (P < 0.01) (Figure 2F). In
addition, the rate of change assessed by the slope test
indicated signiﬁcantly more rapid tumor growth in the
HFHC group compared with the LFNC group (F Z 2.05,
PZ 0.04), with mean tumor volume signiﬁcantly higher on
day 19 (P Z 0.008), day 22 (P Z 0.003), and day 25
(PZ 0.004) (Figure 2E). There was no synergistic effect of2104ezetimibe treatment and LFNC diet on tumor growth
(Figure 2G). Tumor take was >95% in all groups, and no
signiﬁcant differences in tumor take between groups were
observed.
We expected that long-term maintenance on the HFHC
diet might increase serum triglycerides; conversely, ezeti-
mibe has been reported to exert a modest reduction of tri-
glyceride levels in humans.38 However, in the present study,
triglyceride levels were within the normal range for all
groups, and the treatment of ezetimibe did not result in any
changes in serum triglycerides. Notably, triglyceride levels
were signiﬁcantly lower in the HFHC cohorts (data not
shown). Serological testing (aspartate aminotransferase,
alkaline phosphatase, and bilirubin) indicated no liver
dysfunction in any of the mice (data not shown). We ex-
pected that intratumoral cholesterol levels would reﬂect the
different serum cholesterol levels of the diet and treatment
groups; however, when assayed, no difference in intra-
tumoral cholesterol levels was observed (P Z 0.825, anal-
ysis of variance) (Figure 2H).
Given that the intratumoral cholesterol levels did not
differ between diet/drug groups, we further examined
whether hypercholesterolemia was inducing tumor pro-
gression, independent of diet and drug treatment. We
deﬁned hypercholesterolemia as serum cholesterol levels 2
SDs higher than the mean cholesterol level of age-matched,
sex-matched mice on a normal (not high-fat) diet. In this
study, the mean cholesterol value plus 2 SDs was 124
mg/dL. Therefore, mice having terminal serum cholesterol
levels of 124 mg/dL were characterized as being hyper-
cholesterolemic. Blinded to diet and drug treatment, we
separated hypercholesterolemic mice from mice with normal
serum cholesterol levels and compared the tumor volume
between these two groups. A t-test of the means revealed
that the ﬁnal tumor volume of hypercholesterolemic mice
was signiﬁcantly greater than the tumor volume in mice
with normal serum cholesterol levels, independent of treat-
ment group (P Z 0.007, t-test) (Figure 3A). The mean
difference between the two subgroups was 168 mm3. The
strength of this ﬁnding is represented by the 95% CI (48 to
298 mm3), indicating that animals with hypercholesterole-
mia are expected to have signiﬁcantly larger tumor volumes
in the range of 48 to 298 mm3 larger. In addition, in an
analysis blinded to treatment, the Pearson correlation
showed the relationship between serum cholesterol and total
tumor volume is positive (Pearson r Z 0.23, P Z 0.018)
and clearly reveals an association that animals with higher
serum cholesterol have high tumor volumes.
Notably, a comparison of insulin levels observed between
these two cholesterol groups (normal versus hypercholes-
terolemia, <124 versus 124 mg/dL) revealed that serum
insulin levels did not differ (PZ 0.477, t-test) (Figure 3B). In
addition, in an analysis blinded to treatment, no relationship
between serum cholesterol and serum insulin existed (Pear-
son rZ0.01, PZ 0.93). This further demonstrates that the
isocaloric diet strategy used in this study inducesajp.amjpathol.org - The American Journal of Pathology
Figure 4 Tumor apoptosis is signiﬁcantly reduced in mice fed the HFHC diet. A: TUNEL staining. Top row: Representative tumor sections for each group
with TUNEL staining (green). Bottom row: Merged image of tumor section with TUNEL stain (green) and nuclei counterstained with DAPI (blue). B: Quan-
tiﬁcation of tumor cell apoptosis. The level of tumor apoptosis plotted as average percentage of TUNEL-positive cells  SEM versus diet/drug group. Tumors
from animals fed an HFHC diet had less apoptotic tumor cells compared with the other diet/drug groups (FZ 9.67, P < 0.001, repeated-measures analysis of
variance). *P  0.007 (Bonferroni’s multiple-comparison test), signiﬁcant difference between the HFHC group and the HFHC þ ezetimibe (Z), LFNC, and LFNC
þ Z groups; yP Z 0.012 (Bonferroni’s multiple-comparison test), signiﬁcant difference between the HFHC þ Z and LFNC þ Z groups. No difference in tumor
apoptosis was seen between the LFNC þ Z and LFNC groups (P Z 0.357) (n Z 70 images per group).
Cholesterol Promotes Breast Tumor Growthhypercholesterolemia that is not associated with hyper-
insulinemia and does not increase serum insulin levels
(Figure 3B).
Next, we asked whether insulin levels are associated with
tumor volume. Independent of diet and drug treatment, we
grouped the mice with the highest serum insulin levels
(deﬁned as 2 SDs higher than the mean or 1.0 ng/mL)
from those mice with normal cholesterol levels (<1.0 ng/
mL) and found that those animals possessing the highest
insulin levels did not have the highest tumor volume. A
comparison of the mean tumor volume of high insulin mice
(those with 1.0 ng/mL) versus those with normal insulin
levels (<1.0 ng/mL) revealed no difference (P Z 0.377,Figure 5 Tumor cell proliferation is signiﬁcantly increased in mice fed the HFH
for each group stained for Ki-67 (red), a proliferation marker. Bottom row: Images
B: Quantiﬁcation of tumor cell proliferation. The level of tumor cell proliferation pl
group. Tumors from the animals fed the HFHC have a signiﬁcantly greater perc
(F Z 17.62, P < 0.001, analysis of variance and Bonferroni’s multiple-compariso
with the HFHC group, no difference in tumor proliferation was seen between H
comparison tests, P  0.665) (n Z 50 images per group).
The American Journal of Pathology - ajp.amjpathol.orgt-test) (Figure 3C). A regression analysis of insulin (blinded
to diet and drug treatment group) revealed that serum insulin
level has no association with tumor volume (F Z 0.047,
P Z 0.828) and, therefore, high serum insulin level itself
did not predict increased tumor volume in this study
(Pearson r Z 0.140, P Z 0.30).
Taken together, these data demonstrate that high serum
cholesterol levels (independent of diet and drug treat-
ment) are predictive of greater mean tumor volume,
whereas insulin levels are not. In addition, high and low
serum cholesterol groups do not differ with respect to
mean insulin levels. These data demonstrate that high
serum cholesterol is exerting the observed effectsC diet. A: Ki-67 staining. Top row: Representative images of tumor sections
of Ki-67 staining (red) merged with nuclei counterstained with DAPI (blue).
otted as average percentage of Ki-67epositive cells  SEM versus diet/drug
entage of proliferating cells compared with tumors from all other groups
n tests, P < 0.001). The asterisk indicates signiﬁcant difference compared
FHC þ ezetimibe (Z), LFNC, and LFNC þ Z groups (Bonferroni’s multiple-
2105
Figure 6 Tumor angiogenesis is signiﬁcantly greater in tumors from mice fed an HFHC diet. A: CD31 staining. Representative immunoﬂuorescent images of
tumor sections from each group stained for the endothelial cell marker, CD31 (green). Images of the CD31-stained panel (green) merged with nuclei
counterstained with DAPI (blue). B: Quantiﬁcation of MVD. Data are plotted as relative level of CD31 staining versus diet/ezetimibe (Z) group  SEM. Data
were analyzed by mixed-model analysis of variance, which indicates a signiﬁcantly greater vessel area in tumors from mice fed an HFHC diet compared with
animals receiving ezetimibe (Z) and/or receiving an LFLC diet (F Z 18.06, P < 0.001). **P < 0.01 (Bonferroni’s multiple-comparison test), signiﬁcant
difference compared with HFHC group, whereas no difference in MVD was observed between LFNC þ Z and HFHC þ Z groups (Bonferroni’s multiple comparison
test, P Z 0.502) (n Z 80 images per group).
Pelton et alindependent of insulin on tumor volume and supports the
conclusion that hypercholesterolemia is associated with
higher tumor volume.
To investigate the mechanisms underlying the tumor-
promoting effect of elevated cholesterol, we analyzed the
tumors using a variety of approaches. Apoptosis and cell
proliferation were evaluated quantitatively in the tumors.
Apoptosis, quantiﬁed by TUNEL staining, was signiﬁcantly
suppressed in tumors frommice in theHFHCgroup,which had
39% apoptotic cells compared with 49% and 52% apoptotic
cells in tumors from the LFNC, with or without ezetimibe,
groups and 58% apoptotic cells in the HFHC þ ezetimibe
group (FZ 9.67, P< 0.01) (Figure 4, A and B). However, noFigure 7 Tumors from animals treated with ezetimibe have signiﬁcantly gre
ﬂuorescent images of tumor sections from each group stained for the endothelia
Images of CD31 (green) and SMA (red) stained tumors merged with the nuclei coun
Data are plotted as the average percentage of SMA coverage of CD31-positive micro
treated tumors had signiﬁcantly greater SMA staining (greater vessel stability) com
There was no effect of diet on vessel stability (no difference in % SMA staining
multiple-comparison test), signiﬁcant difference from the HFHC group; yP  0.0
LFNC group (n Z 50 images per group).
2106synergy was observed between LFNC diet and ezetimibe
use, and tumors from HFHC þ ezetimibe treated mice had
signiﬁcantly more apoptotic cells than tumors from LFNC þ
ezetimibe treated mice (PZ 0.012) (Figure 4B).
Importantly, cell proliferation, as measured by Ki-67
staining, was signiﬁcantly greater in the tumors grown in
the HFHC-fed mice (51%) (Figure 5A), whereas a signiﬁ-
cantly decreased percentage of proliferating tumor cells was
observed in the groups with lower circulating cholesterol
[ie, those receiving ezetimibe (33% and 33%) and/or the
LFNC diet (32.5%)] (F Z 17.62, P < 0.001) (Figure 5B).
Microvessel density (MVD) in the breast tumors was
quantiﬁed using an antibody for CD31 (platelet endothelialater perivascular cell coverage. A: SMA staining. Representative immuno-
l cell marker, CD31 (green), and for the perivascular cell marker SMA (red).
terstained with DAPI (blue). B: Quantiﬁcation of perivascular cell coverage.
vessels  SEM versus diet/drug group and demonstrate that ezetimibe (Z)e
pared with untreated tumors (FZ 5.916, PZ 0.001, analysis of variance).
), mixed-model analysis of variance, P Z 0.842. *P  0.01 (Bonferroni’s
18 (Bonferroni’s multiple-comparison test), signiﬁcant difference from the
ajp.amjpathol.org - The American Journal of Pathology
Cholesterol Promotes Breast Tumor Growthcell adhesion molecule 1), an endothelial cell marker. MVD
was signiﬁcantly suppressed by both ezetimibe and by the
LFNC diet when compared with the HFHC diet (FZ 18.06,
P < 0.001) (Figure 6, A and B). MVD was not a reﬂection
of tumor size because tumors of similar mass were exam-
ined for each treatment group.43,44
Given the signiﬁcant effect of high cholesterol on tumor
microvessel density and given our previous ﬁnding that
thrombospondin (TSP-1), the endogenous, angiogenesis in-
hibitor, was decreased in prostate tumors from mice fed an
HFHC diet,24 we asked whether TSP-1 expression might be
suppressed by hypercholesterolemia in breast tumors as well.
After conducting a thorough quantitative analysis of TSP-1
expression in eight tumors per group (>80 images) and
after calculating the areas of positive staining and corrected
total cell ﬂuorescence, we found, interestingly, that although
signiﬁcant differences could be observed in TSP-1 expression
between tumors in the HFHC and LFNCþ Z diet groups (the
groups with the lowest and highest MVD, respectively), no
signiﬁcant overall correlation between TSP-1 expression and
tumor microvessel density was detected (data not shown).
Blood vessels undergoing rapid angiogenesis in tumors
tend to exhibit poor vascular morphological characteristics,
characterized by low perivascular cell coverage.45 Vessel
stability was quantiﬁed in tumor sections by comparing the
perivascular cell marker, SMA staining, to total vessel stain-
ing (CD31). A signiﬁcant increase in perivascular cell
coverage was seen in the ezetimibe-treated groups (Figure 7,
A andB), suggesting a stabilizing effect of ezetimibe on tumor
vascular structure. There was no synergistic effect of low-fat
diet and ezetimibe on blood vessel stability (Figure 7B).
Collectively, these results indicate a pronounced effect of
circulating cholesterol on tumor neovascularization.Discussion
Herein, we demonstrate that a high-fat, high-cholesterol,
Western diet that signiﬁcantly increases circulating choles-
terol levels promotes the growth of human breast tumors in
an orthotopic mouse model of breast cancer. We also
demonstrate that targeting cholesterol by use of a low-fat,
no-cholesterol diet or use of ezetimibe, a speciﬁc hypo-
cholesterolemic agent, reduces circulating cholesterol and
results in slower tumor growth. Our conclusion that these
effects can be attributed to cholesterol is supported by the
following evidence: i) The fastest-growing tumors were
found in the cohort with the highest serum cholesterol
levels. ii) We used isocaloric diets and body mass did not
differ signiﬁcantly between groups, eliminating any poten-
tial effect of energy imbalance on tumor growth. iii)
Cholesterol was speciﬁcally targeted and lowered with the
drug ezetimibe (Zetia). iv) The diet interventions did not
affect circulating estrogen or insulin levels; consequently,
insulin levels were not associated with tumor volume. v) All
liver function tests were within the normal range for allThe American Journal of Pathology - ajp.amjpathol.orgtreatment groups. vi) The cohort of mice with the highest
cholesterol levels had tumors with signiﬁcantly less
apoptotic cells, signiﬁcantly more proliferating cells, and
signiﬁcantly higher levels of MVD. To our knowledge, our
results are the ﬁrst to conclusively implicate hypercholes-
terolemia in breast cancer progression.
The current study examines the effect of cholesterol on
breast cancer progression in an orthotopic adult mouse
model. Although several interesting reports have investi-
gated the relationship between a Western diet and breast
cancer, our report is the ﬁrst, to our knowledge, to experi-
mentally control for calorie intake, obesity, dyslipidemia,
serum insulin, and triglyceride levels, and to directly
implicate the effects of dietary cholesterol by pharmaco-
logically targeting and reducing cholesterol.27 By initiating
the Western diet after 8 weeks of age, after development of
the mature mammary gland is complete, the role of dietary
cholesterol on breast cancer can be separated from the effect
of diet on mammary gland development in our study, in
contrast to prior reports.27 Another recent report using
orthotopic injection of mouse mammary carcinoma cells
into wild-type and ApoE/ transgenic mice examined the
effect of dyslipidemia on mammary cancer growth and
metastasis.28 This study used a high-fat, high-cholesterol
diet that resulted in weight gain in both the wild-type mouse
and the ApoE/ mice and high serum cholesterol levels in
the wild-type and severe, lethal, hypercholesterolemic
(approximately 2000 mg/dL), and increased plasma tri-
glyceride levels in the ApoE/ mice. To unequivocally
determine the speciﬁc role of cholesterol on breast cancer
progression, we chose to compare an HFHC diet that raised
cholesterol signiﬁcantly but modestly with an LFNC diet
and to speciﬁcally target cholesterol while maintaining
normal mouse weight, normal serum insulin, and normal
plasma triglyceride levels.
It is not unexpected that neither our current study nor
those of others27 did not ﬁnd increasing levels of cholesterol
in the membranes of breast tumor cells as serum cholesterol
levels increase. Although it has been shown that circulating
lipoproteins and lipid rafts can alter growth and intracellular
signaling properties of breast cells,9 there is no direct evi-
dence that loss of normal cholesterol homeostasis occurs in
the ductal epithelia of the breast. This is in contrast to
our prior study of prostate cancer, where prostate tumor
cholesterol levels increase with increasing serum cholesterol
levels,24e26 a ﬁnding that is consistent with the literature
showing that both aged normal and malignant prostate
ductal epithelial cells lose their ability to regulate cholesterol
levels normally.46
As mentioned previously, cholesterol homeostasis differs
in mouse and humans [namely, most of the circulating
cholesterol in the mouse is high-density lipoprotein (HDL)
versus low-density lipoprotein (LDL) in humans]. This
difference is unlikely to affect our study in such a manner as
to alter our conclusions because it is not a reﬂection of
functional species distinctions, because LDL (which2107
Pelton et altransports cholesterol into cells) and HDL (which transports
cholesterol away from cells) function similarly in mice and
humans. Rather, this difference is simply a product of
different cholesterol turnover rates in mice versus humans.33
More important with respect to our study is the fact that the
major apolipoproteins of LDL (apolipoprotein B) and HDL
(apolipoprotein A1) are highly conserved between mouse
and human, as is the LDL receptor (76% homology on the
DNA level).47 It is also widely appreciated that both human
and mouse LDL receptor can bind and uptake both mouse
and human LDL.48,49 In addition, we have performed ex-
periments in which we increased murine serum cholesterol
levels and achieved substantial increases in cellular
cholesterol in human cells that exhibit poor cholesterol
efﬂux, demonstrating that cross-species cholesterol transport
can successfully occur in our hybrid model(s).24
Although our ﬁndings that cholesterol regulation of some
of the growth properties of breast cancer are robust, there is
an absence of strong, consistent epidemiological data
demonstrating that cholesterol-lowering drugs reduce the
incidence of breast cancer. One potential reason for this lack
of conclusive epidemiological evidence is that the median
age of breast cancer diagnosis is 61 years, whereas the mean
age of statin-using women is >60 years.50 Therefore, far
fewer women with breast cancer have used statins for >5
years compared with subjects in similar studies focusing on
prostate cancer and statin use among men.51,52 Moreover, in
general, fewer women are prescribed a statin than men.53
Taken together, these data suggest that the absence of
robust epidemiological data demonstrating an effect of sta-
tins on breast cancer may simply be because fewer women
use statins for shorter periods than men, and there are
insufﬁcient patients to derive statistically signiﬁcant results.
In these studies, we demonstrate that ezetimibe blocks the
accelerated tumor growth stimulated by the HFHC diet.
Ezetimibe works by blocking intestinal uptake of dietary
cholesterol and bile-derived cholesterol; therefore, the drug
is expected to reduce circulating cholesterol levels when
cholesterol is both present and absent from the diet.36e38
Unlike statins, which block cholesterol synthesis at an
early step in the mevalonate pathway and, thus, suppress
production of upstream intermediates (including iso-
prenoids), ezetimibe blocks cholesterol uptake and likely
has no direct effect on other components of the pathway.
An important effect elicited by the manipulation of
circulating cholesterol levels was its impact on tumor
angiogenesis. Our studies revealed that reducing cholesterol
levels reduces the amount of blood vessels, and that ezeti-
mibe increases vessel perivascular cell coverage (suggesting
a more stable vascular structure). These results demonstrate
that a major biological effect of hypercholesterolemia on
breast tumors is increased angiogenesis. Our ﬁnding that the
endogenous angiogenesis inhibitor, TSP-1, although
expressed at lowest levels in tumors from the HFHC diet
group (where MVD was the highest), did not signiﬁcantly
correlate with tumor MVD (data not shown) suggests that2108regulation of angiogenesis in breast cancer may be more
complex than that of prostate and other cancers and opens
up the exciting possibility that other regulators of angio-
genesis may be playing an important role. This observation,
although beyond the scope of the current study, merits
further investigation. Our ﬁnding that ezetimibe-treated
animals had improved perivascular cell coverage of ves-
sels highlights a novel potential role for ezetimibe in the
stabilization of tumor vasculature. Vessels of untreated an-
imals receiving the LFNC diet, with circulating cholesterol
levels similar to ezetimibe-treated animals, did not exhibit
the extent of perivascular cell coverage and vessel stability
that was observed in either of the ezetimibe-treated groups,
suggesting that this result may be independent of the
cholesterol-lowering properties of ezetimibe. The potential
for ezetimibe to contribute to the normalization of tumor
vasculature opens the possibility of ezetimibe synergizing
with the effect of chemotherapeutic and tumor-targeting
agents, a phenomenon that could have important clinical
implications.
One potential mechanism to explain how cholesterol may
be inducing tumor progression in the absence of intra-
tumoral accumulation of cholesterol would be through the
up-regulation of cholesterol-derived steroid hormones, such
as androgens within the tumor. Although we demonstrated
that estrogen levels are not altered by diet or by drug
treatment, examination of androgen levels and androgen
receptor expression and subcellular localization within the
tumor warrant further examination, especially in light of
recent reports demonstrating increased androgen signaling
in triple-negative breast cancers.54 Given that the MDA-
MB-231 breast cancer cells used in this study are triple
negative, this potential androgen-associated mechanism of
cholesterol-induced tumor progression is distinct from
others that have been proposed55 because the MDA-MB-
231 cells are estrogen receptor negative. The enhanced
tumor angiogenesis observed in mice fed an HFHC diet in
the current study suggests that monocyte and macrophage
recruitment into the tumor may be one plausible mechanism
to explain how hypercholesterolemia is inducing tumor
progression in the absence of increased intratumoral
cholesterol. This is an intriguing potential mechanism,
especially given that hypercholesterolemia is known to in-
crease monocyte and macrophage adhesion to vascular
endothelium56 and given that it has been shown that tumor-
associated macrophages contribute to breast tumor angio-
genesis and progression.57
Our results demonstrating that treatment of hypercholes-
terolemia with diet and/or with ezetimibe suppresses the
growth of breast tumors in vivo are consistent with, and
complement, the most recent prospective epidemiological
studies reporting an association between statin use and
decreased incidence of breast cancer recurrence in women
diagnosed with stage I to III breast cancer.19e21 They also
suggest the possibility that chemopreventive intervention to
inhibit breast cancer progression by lowering cholesterolajp.amjpathol.org - The American Journal of Pathology
Cholesterol Promotes Breast Tumor Growthpharmacologically, possibly in combination with diet, may
be clinically effective. This study raises the possibility that
cholesterol reduction, which is routinely accomplished
through pharmacological and non-pharmacological means
in humans, may reduce tumor neovascularization, ultimately
leading to less aggressive tumors.References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global
cancer statistics. CA Cancer J Clin 2011, 61:69e90
2. ShimizuH,RossRK,Bernstein L, Yatani R, HendersonBE,Mack TM:
Cancers of the prostate and breast among Japanese and white
immigrants in Los Angeles County. Br J Cancer 1991, 63:963e966
3. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N:
Are imprecise methods obscuring a relation between fat and breast
cancer? Lancet 2003, 362:212e214
4. Emaus A, Veierød MB, Tretli S, Finstad SE, Selmer R, Furberg AS,
Bernstein L, Schlichting E, Thune I: Metabolic proﬁle, physical ac-
tivity, and mortality in breast cancer patients. Breast Cancer Res Treat
2010, 121:651e660
5. Owiredu WK, Donkor S, Addai BW, Amidu N: Serum lipid proﬁle of
breast cancer patients. Pak J Biol Sci 2009, 12:332e338
6. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE:
Adult weight change and risk of postmenopausal breast cancer.
JAMA 2006, 296:193e201
7. Simons K, Ikonen E: How cells handle cholesterol. Science 2000,
290:1721e1726
8. Soccio RE, Breslow JL: Intracellular cholesterol transport. Arte-
rioscler Thromb Vasc Biol 2004, 24:1150e1160
9. Danilo C, Frank PG: Cholesterol and breast cancer development. Curr
Opin Pharmacol 2012, 12:677e682
10. Kaye JA, Meier CR, Walker AM, Jick H: Statin use, hyperlipidaemia,
and the risk of breast cancer. Br J Cancer 2002, 86:1436e1439
11. Desager JP, Horsmans Y: Clinical pharmacokinetics of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet
1996, 31:348e371
12. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK,
Daling JR: The association between 3-hydroxy-3-methylglutaryl coen-
zyme A inhibitor use and breast carcinoma risk among postmenopausal
women: a case-control study. Cancer 2004, 100:2308e2316
13. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC,
Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT;
Women’s Health Initiative Research Group: Statin use and breast
cancer: prospective results from the Women’s Health Initiative. J Natl
Cancer Inst 2006, 98:700e707
14. Fagherazzi G, Fabre A, Boutron-Ruault MC, Clavel-Chapelon F:
Serum cholesterol level, use of a cholesterol-lowering drug, and
breast cancer: results from the prospective E3N cohort. Eur J Cancer
Prev 2010, 19:120e125
15. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL,
Cummings SR, Bauer DC: Lipid-lowering drug use and breast cancer
in older women: a prospective study. J Womens Health (Larchmt)
2003, 12:749e756
16. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH,
Esserman LJ: Estrogen receptor-negative breast cancer is less likely to
arise among lipophilic statin users. Cancer Epidemiol Biomarkers
Prev 2008, 17:1028e1033
17. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM: Long-term use of
cholesterol-lowering drugs and cancer incidence in a large United
States cohort. Cancer Res 2011, 71:1763e1771
18. Kitahara CM, Berrington de González A, Freedman ND, Huxley R,
Mok Y, Jee SH, Samet JM: Total cholesterol and cancer risk in a
large prospective study in Korea. J Clin Oncol 2011, 29:1592e1598The American Journal of Pathology - ajp.amjpathol.org19. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP,
Silliman RA, Sørensen HT, Lash TL: Statin prescriptions and breast
cancer recurrence risk: a Danish nationwide prospective cohort study.
J Natl Cancer Inst 2011, 103:1461e1468
20. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D,
Desai A, Tester W: Reduced risk of breast cancer recurrence in pa-
tients using ACE inhibitors, ARBs, and/or statins. Cancer Invest
2011, 29:585e593
21. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B: Post-
diagnosis statin use and breast cancer recurrence in a prospective
cohort study of early stage breast cancer survivors. Breast Cancer Res
Treat 2008, 109:573e579
22. Solomon KR, Freeman MR: Do the cholesterol-lowering properties
of statins affect cancer risk? Trends Endocrinol Metab 2008, 19:
113e121
23. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D,
Schaffner CP, Kim J, Freeman MR: Ezetimibe is an inhibitor of
tumor angiogenesis. Am J Pathol 2009, 174:1017e1026
24. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Choles-
terol targeting alters lipid raft composition and cell survival in pros-
tate cancer cells and xenografts. J Clin Invest 2005, 115:959e968
25. Mostaghel EA, Solomon KR, Pelton K, Freeman MR,
Montgomery RB: Impact of circulating cholesterol levels on growth
and intratumoral androgen concentration of prostate tumors. PLoS
One 2012, 7:e30062
26. Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F,
Williams TM, Sotgia F, Lisanti MP, Frank PG: Role of cholesterol in
the development and progression of breast cancer. Am J Pathol 2011,
178:402e412
27. Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ,
Scheinman EJ, Yakar S, LeRoith D: Mammary tumor growth and
pulmonary metastasis are enhanced in a hyperlipidemic mouse model.
Oncogene 2013, 32:961e967
28. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL,
Strong RK, Zurakowski D, Moses MA: Lipocalin 2 promotes breast
cancer progression. Proc Natl Acad Sci U S A 2009, 106:3913e3918
29. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA: ADAM12
transmembrane and secreted isoforms promote breast tumor growth: a
distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem
2011, 286:20758e20768
30. Boucher K, Siegel CS, Sharma P, Hauschka PV, Solomon KR:
HMG-CoA reductase inhibitors induce apoptosis in pericytes.
Microvasc Res 2006, 71:91e102
31. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M,
Kim CC, Klagsbrun M: Semaphorin 3F, a chemorepulsant for
endothelial cells, induces a poorly vascularized, encapsulated, non-
metastatic tumor phenotype. J Clin Invest 2004, 114:1260e1271
32. Endo A, Tsujita Y, Kuroda M, Tanzawa K: Effects of ML-236B on
cholesterol metabolism in mice and rats: lack of hypocholesterolemic
activity in normal animals. Biochim Biophys Acta 1979, 575:
266e276
33. Dietschy JM, Turley SD: Control of cholesterol turnover in the
mouse. J Biol Chem 2002, 277:3801e3804
34. Endo A: Chemistry, biochemistry, and pharmacology of HMG-CoA
reductase inhibitors. Klin Wochenschr 1988, 66:421e427
35. Tang W, Ma Y, Yu L: Plasma cholesterol is hyperresponsive to statin
in ABCG5/ABCG8 transgenic mice. Hepatology 2006, 44:
1259e1266
36. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G,
Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N,
Graziano MP: Niemann-Pick C1 like 1 protein is critical for intestinal
cholesterol absorption. Science 2004, 303:1201e1204
37. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J,
Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP,
Altmann SW: Niemann-Pick C1 like 1 (NPC1L1) is the intestinal
phytosterol and cholesterol transporter and a key modulator of whole-
body cholesterol homeostasis. J Biol Chem 2004, 279:33586e335922109
Pelton et al38. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ,
LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group:
Effects of ezetimibe, a new cholesterol absorption inhibitor, on
plasma lipids in patients with primary hypercholesterolemia. Eur
Heart J 2003, 24:729e741
39. Jia L, Betters JL, Yu L: Niemann-pick C1-like 1 (NPC1L1) protein in
intestinal and hepatic cholesterol transport. Annu Rev Physiol 2011,
73:239e259
40. Lichtman AH, Clinton SK, Iiyama K, Connelly PW, Libby P,
Cybulsky MI: Hyperlipidemia and atherosclerotic lesion development
in LDL receptor-deﬁcient mice fed deﬁned semipuriﬁed diets with and
without cholate. Arterioscler Thromb Vasc Biol 1999, 19:1938e1944
41. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W,
Demer LL: Atherogenic high-fat diet reduces bone mineralization in
mice. J Bone Miner Res 2001, 16:182e188
42. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-
WahnefriedW, AronsonWJ, Cohen P, HwangD, Peterson B, Fields T,
Pizzo SV, IsaacsWB:Carbohydrate restriction, prostate cancer growth,
and the insulin-like growth factor axis. Prostate 2008, 68:11e19
43. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA: The
matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin
complex plays a role in breast tumor growth and is present in the
urine of breast cancer patients. Clin Cancer Res 2005, 11:5390e5395
44. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ,
Moses MA: The anti-angiogenic peptide, loop 6, binds insulin-like
growth factor-1 receptor. J Biol Chem 2010, 285:41886e41895
45. Bergers G, Song S: The role of pericytes in blood-vessel formation
and maintenance. Neuro Oncol 2005, 7:452e464
46. Schaffner CP: Prostatic cholesterol metabolism: regulation and
alteration. Prog Clin Biol Res 1981, 75A:279e324
47. Hoffer MJ, van Eck MM, Petrij F, van der Zee A, de Wit E, Meijer D,
Grosveld G, Havekes LM, Hofker MH, Frants RR: The mouse low
density lipoprotein receptor gene: cDNA sequence and exon-intron
structure. Biochem Biophys Res Commun 1993, 191:880e886
48. Masquelier M, Vitols S, Peterson C: Low-density lipoprotein as a
carrier of antitumoral drugs: in vivo fate of drug-human low-density
lipoprotein complexes in mice. Cancer Res 1986, 46:3842e3847211049. Young SG, Witztum JL, Casal DC, Curtiss LK, Bernstein S: Con-
servation of the low density lipoprotein receptor-binding domain of
apoprotein B: demonstration by a new monoclonal antibody, MB47.
Arteriosclerosis 1986, 6:178e188
50. Walsh JM, Pignone M: Drug treatment of hyperlipidemia in women.
JAMA 2004, 291:2243e2252
51. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP,
Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr,
Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ: Statin use and risk
of prostate cancer in the California Men’s Health Study Cohort.
Cancer Epidemiol Biomarkers Prev 2007, 16:2218e2225
52. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ,
Willett WC, Giovannucci E: Statin drugs and risk of advanced
prostate cancer. J Natl Cancer Inst 2006, 98:1819e1825
53. US Department of Health and Human Services. Health, United States,
2010: with special feature on death and dying. Hyattsville (MD):
National Center for Health Statistics (US). DHHS Pub No. 2011-
1232. Available from: US Government Printing Ofﬁce, Washington,
DC; 76-641496
54. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ,
Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP,
Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA: Androgen
receptor-positive triple negative breast cancer: a unique breast cancer
subtype. Ann Surg Oncol 2014, 21:361e367
55. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S,
Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V,
Umetani M, Geradts J, McDonnell DP: 27-Hydroxycholesterol links
hypercholesterolemia and breast cancer pathophysiology. Science
2013, 342:1094e1098
56. Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC,
Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM: Functional
role of CD11cþ monocytes in atherogenesis associated with hyper-
cholesterolemia. Circulation 2009, 119:2708e2717
57. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J,
Harris AL: Association of macrophage inﬁltration with angiogenesis
and prognosis in invasive breast carcinoma. Cancer Res 1996, 56:
4625e4629ajp.amjpathol.org - The American Journal of Pathology
